SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Valvoline, Inc. engages in the production, marketing, and supply of engine and automotive maintenance products and services. It operates through the Retail Services segment. The Retail Services segment services the passenger car and light truck quick lube market in the US and Canada with preventive maintenance services done through company operated and independent franchise care stores. The company was founded by John Ellis in 1866 and is headquartered in Lexington, KY.

Valvoline Inc

Valvoline is trending as analysts adjust price targets and ratings, following news of Piper Sandler and Stephens & Co. setting overweight ratings. The community highlights potential for new store openings and expansion into electric vehicle services, viewing it as a safe, long-term investment. Bullish sentiment suggests potential to test all-time highs, with some eyeing it as an 'easy money' opportunity.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as the community discusses its potential, particularly following integrations with Abstract Chain and Shogun, which enable new functionalities like cross-chain triggers and AI-driven DeFi automation.  Enthusiasm centers around the project's technology and speculation about future listings, along with anticipation for the sunsetting of $PRQ, which some believe is currently limiting REACT's price action. Some community members express very high hopes for the token.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is gaining attention as it expands across multiple chains like Solana, BNB, and Base. Community members highlight its fully circulated supply and deflationary burn mechanism, contributing to its increasing popularity. Traders are watching its growing presence on various exchanges, with some suggesting it could be the next big meme coin.

ProShares Trust - ProShares VIX Mid-Term Futures ETF

ProShares VIX Mid-Term Futures ETF

VIXM is trending as traders discuss potential government shutdowns and the accumulation of volatility insurance amid frothy market conditions. Community members are exploring VIXM leaps and comparing it to other volatility hedges like $VIXY, noting its potential for minimal decay and suitability for longer holding periods. Some traders suggest VIXM could be a strategic play given historical patterns of increased volatility in October.

Hasbro, Inc. engages in the provision of children and family leisure time products and services with a portfolio of brands and entertainment properties. The firm's brands of toys include Power Rangers, Magic: The Gathering, Monopoly, My Little Pony, Nerf, Play-Doh and Transformers. It operates through the following segments: Consumer Products, Wizards of the Coast and Digital Gaming, Entertainment, and Corporate and Other. The Consumer Products segment markets and sells toys and game products around the world. It also promotes brands through the out-licensing of trademarks, characters and other brand and intellectual property rights to third parties, and through the sale of branded consumer products such as toys and apparel. The Wizards of the Coast and Digital Gaming segment promotes the company's brands through the development of trading cards, role-playing and digital game experiences based on Hasbro and Wizards of the Coast properties. The Entertainment segment develops and distributes entertainment content including film, scripted and unscripted television, children's programming, digital content, and live entertainment. The Corporate and Other segment includes the management and administrative services to its principal reporting segments. The company was founded by Henry Hassenfeld and Hilal Hassenfeld in 1923 and is headquartered in Pawtucket, RI.

Hasbro, Inc.

Hasbro ($HAS) is trending due to unusual options activity signaling bullish sentiment and upcoming earnings, particularly driven by the performance of Magic: The Gathering. Community members are discussing the potential impact of the Lord of the Rings set and digital gaming growth on Hasbro's financials. As a consumer discretionary stock, Hasbro is also being considered in light of potential Fed rate cuts.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as it approaches its halving event, with the community actively discussing its potential for significant gains and its privacy features in light of increased regulatory scrutiny on crypto. Some are drawing comparisons to Bitcoin's early days, while others point to ZEC's shielded transactions as a key differentiator for institutional adoption. There's also excitement around new integrations and developments within the Zcash ecosystem.

Green Satoshi Token

GSTSOL is trending as traders discuss its potential for a significant breakout, with some pointing to its low market cap and historical price movements as indicators for a possible surge. Community members are actively monitoring volume and chart patterns, speculating about a potential pump and looking for signs of increased buying pressure. Some users suggest the STEPN app could drive future token demand.

Hydrex is the MetaDEX & Liquidity Infrastructure purpose-built for Base. By combining automated strategies, liquid-backed tokenomics, and Base's powerful distribution channels, Hydrex removes the barriers to yield. It's designed as a coordination system where weekly community governance directs HYDX emissions & protocol revenue. Value flows to where liquidity and volume are most productive, based on protocol alignment.

Hydrex

Hydrex ($HYDX) is trending as traders discuss its potential as an Aero competitor and highlight its recent price action. The community is focused on its launch on Base as a DUNA protocol with locked tokenomics and revenue flow, as well as speculation around potential exchange listings and social media buzz driving gains. Some are drawn to its low market cap and potential for quick gains relative to other crypto projects.

Vital Farms, Inc. packages, markets and distributes pasture-raised shell eggs, pasture-raised butter and other products. Its products are sold under the trade names Vital Farms, Alfresco Farms, Lucky Ladies and RedHill Farms, primarily to retail foodservice channels. The company was founded by Catherine Stewart, Matthew O'Hayer and Jason Jones in 2007 and is headquartered in Austin, TX.

Vital Farms Inc

VITL is trending as investors discuss the stock's recent pullback after earnings gains, with some questioning if its uptrend is over. Unusual options activity indicates a bearish sentiment, while others in the community highlight positive aspects such as analyst ratings and long-term growth potential within the consumer staples sector. The stock's squeezability score and upcoming price targets are also being actively discussed.

Pembina Pipeline Corp. engages in the provision of transportation and midstream services. It operates through the following segments: Pipelines, Facilities, Marketing and New Ventures, and Corporate. The Pipelines segment includes conventional, oil sands and transmission pipeline systems, crude oil storage and terminalling business and related infrastructure. The Facilities segment consists of processing and fractionation facilities and related infrastructure that delivers the firm's customers with natural gas and NGL services. The Marketing and New Ventures segment undertakes value-added commodity marketing activities, including buying and selling products and optimizing storage opportunities. The company was founded on September 29, 1954 and is headquartered in Calgary, Canada.

Pembina Pipeline Corporation

$PBA is trending due to a potential deal to build a massive AI data center in Alberta with Meta Platforms, sparking community discussion around the implications of this collaboration. Investors are also weighing the company's steady yield and infrastructure play against margin compression and commodity price risks. Additionally, recent analyst target raises and a joint venture announcement with KKR are contributing to the stock's activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 12, 2025 - BHVN

Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 12, 2025 - BHVN Faruqi & Faruqi Reminds Biohaven Investors of the Pending...

Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi & Korsinsky

Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi & Korsinsky Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi...

Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related to R&amp;D deals and milestone payments.&nbsp;The expense is set to shave&nbsp;off about $0.26 off its per-share earnings, both on a GAAP and adjusted basis.The update adds to investor caution following the FDA’s recent signal report published on June 30, which named Biogen’s Alzheimer’s treatment Leqembi as one of several drugs flagged for potential post-marketing safety concerns.&nbsp;The report, compiled from the FDA’s FAERS database, represents a push for increased transparency around adverse event reporting.Analysts at RBC Capital said they do not anticipate major regulatory fallout, noting that the data was already publicly available and the risks broadly acknowledged.&nbsp;However, they said the FDA’s move could still create some sentiment overhang for Biogen and other named firms, including Sarepta, Alkermes, Biohaven, Xenon, and Argenx.<a href="https://stocktwits.com/symbol/BIIB">Biogen’s</a> newly itemized R&amp;D charges follow its Q1 decision to present such costs as a separate line item on its income statement.&nbsp;The company stated that these typically include expenses from licensing deals and asset acquisitions, which are accounted for as in-process research and development.Meanwhile, Biogen is advancing its drug pipeline, beginning a Phase 3 study with felzartamab, which can treat a kidney condition known as primary membranous nephropathy.The trial, dubbed Prominent, began dosing patients late last month and will enroll about 180 adults.On Stocktwits, retail sentiment for Biogen was ‘bullish’ amid ‘low’ message volume.Biogen’s stock has declined 13.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Equity

Biohaven Pharma stock tumbles after withdrawal of Dazluma application in EU

Investing.com -- Biohaven Pharma (NYSE: BHVN) shares fell sharply by as much as 21% as the company withdrew its marketing authorization application for Dazluma in Europe, intended to treat spinocerebellar ataxia genotype 3 (SCA3). The stock's downturn followed a brief trading halt due to volatility.

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Deutsche Bank initiates coverage of biopharma stocks, sees 'modest recovery'

Investing.com -- Deutsche Bank initiated coverage on 11 U.S. biopharma stocks in a note Tuesday, assigning Buy ratings to eight companies and Hold ratings to three. 

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia Biohaven Announces FDA Acceptance and Priority Review of...

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation P

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective...

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire NEW HAVEN, Conn., Jan. 7, 2025 NEW HAVEN...

Shares of Biohaven (BHVN) gained in morning trade on Tuesday after the company’s director John W. Childs acquired shares worth $1.04 million on Monday.According <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1935979/000193597924000088/xslF345X05/wk-form4_1735646406.xml">to</a> Biohaven’s U.S. Securities and Exchange Commission (SEC) filing, Childs acquired 29,000 shares of the company for the benefit of John W. Childs Revocable Trust, at an average price of $35.9446 apiece, over 3% lower than the current market price of $37.07.Biohaven is a Connecticut-based biopharmaceutical company that focuses on the discovery and development of drugs across therapeutic areas like neuroscience, immunology, and oncology.Earlier this month, the company reported that it achieved essential milestones in the trial of its experimental drug BHV-1300, intended for use in treating a kidney disease. Biohaven also has other trials underway to treat autoimmune diseases.Analysts at RBC Capital raised their price target for the Biohaven stock to $61 from $58 while maintaining an ‘Outperform’ rating, according to TheFly.However, in November, the company’s spinal muscular atrophy (SMA) trial misfired after it failed to achieve its primary endpoint.Reacting to the news of Childs acquiring company shares, Biohaven stock gained over 4% in morning trade on Tuesday, before paring some of the gains.Retail sentiment on Stocktwits entered the ‘bullish’ territory (58/100), with message volume picking up, too.<figure class="image"><img style="aspect-ratio:649/147;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_31_213107_8d3615ce5c.jpg" alt="BHVN stock sentiment" width="649" height="147"><figcaption>BHVN sentiment and message volume December 31, 2024, as of 11:30 am ET | Source: Stocktwits</figcaption></figure>Overall, though, Biohaven’s shares are down nearly 18.5% over the past month, and 13% year-to-date.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/axsome-therapeutics-stock-tumbles-as-alzheimer-studies-reveal-mixed-results/cJOiJFyRki">Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail Sentiment Remains Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of a biopharmaceutical company | Photo by Bernd Weißbrod/picture alliance via Getty Images

Biohaven Stock Surges After Director Acquires Shares Worth Over $1M: Retail Sentiment Turns Bullish

Earlier this month, Biohaven reported achieving important milestones in the trial of its experimental drug BHV-1300, which is intended for use in the treatment of kidney disease.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

BHVN
Biohaven Pharmaceutical Holding Company Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BHVN News

BHVN Biohaven Pharmaceutical Holding Company Ltd